A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Chung-Shien Lee,1,2 Sandhya Sharma,3 Emily Miao,4 Cheryl Mensah,5 Kevin Sullivan,2 Nagashree Seetharamu2 1Department of Clinical Health Professions, St. John’s University, College of Pharmacy and Health Sciences, Queens, NY 11439, USA; 2Division of Medical Oncology and Hematology, Northwel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8b542e20ae0a4c32b9f76e780154d06b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8b542e20ae0a4c32b9f76e780154d06b
record_format	dspace
spelling	oai:doaj.org-article:8b542e20ae0a4c32b9f76e780154d06b2021-12-02T12:50:56ZA Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity1179-2728https://doaj.org/article/8b542e20ae0a4c32b9f76e780154d06b2020-10-01T00:00:00Zhttps://www.dovepress.com/a-comprehensive-review-of-contemporary-literature-for-epidermal-growth-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Chung-Shien Lee,1,2 Sandhya Sharma,3 Emily Miao,4 Cheryl Mensah,5 Kevin Sullivan,2 Nagashree Seetharamu2 1Department of Clinical Health Professions, St. John’s University, College of Pharmacy and Health Sciences, Queens, NY 11439, USA; 2Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY 11042, USA; 3Department of Hematology and Oncology, Denver Health, Denver, CO 80204, USA; 4Albert Einstein College of Medicine, Bronx, NY, USA; 5Weil Cornell School of Medicine, Department of Hematology and Oncology, Weill Cornell of Medicine, New York, NY, USACorrespondence: Nagashree SeetharamuDivision of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 450 Lakeville Road, Lake Success, NY 11042, USATel +1 516-734-8855Email nseetharamu@northwell.eduAbstract: Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib, have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is a favorable option, but almost all patients develop resistance at some time point. There are no effective treatment options for patients who progress on osimertinib, but ongoing trials will hopefully address this unmet need. The aim of this review is to provide a comprehensive review of the data with EGFR TKIs, management of the toxicities and the ongoing trials with this class of agents.Keywords: non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitorLee CSSharma SMiao EMensah CSullivan KSeetharamu NDove Medical Pressarticlenon-small cell lung cancerepidermal growth factor receptortyrosine kinase inhibitorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 11, Pp 73-103 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Lee CS Sharma S Miao E Mensah C Sullivan K Seetharamu N A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
description	Chung-Shien Lee,1,2 Sandhya Sharma,3 Emily Miao,4 Cheryl Mensah,5 Kevin Sullivan,2 Nagashree Seetharamu2 1Department of Clinical Health Professions, St. John’s University, College of Pharmacy and Health Sciences, Queens, NY 11439, USA; 2Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY 11042, USA; 3Department of Hematology and Oncology, Denver Health, Denver, CO 80204, USA; 4Albert Einstein College of Medicine, Bronx, NY, USA; 5Weil Cornell School of Medicine, Department of Hematology and Oncology, Weill Cornell of Medicine, New York, NY, USACorrespondence: Nagashree SeetharamuDivision of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 450 Lakeville Road, Lake Success, NY 11042, USATel +1 516-734-8855Email nseetharamu@northwell.eduAbstract: Mutations in the epidermal growth factor receptor (EGFR) are common amongst those with non-small cell lung cancer and represent a major factor in treatment decisions, most notably in the advanced stages. Small molecule tyrosine kinase inhibitors (TKIs) that target the EGFR, such as erlotinib, gefitinib, icotinib, afatinib, dacomitinib and osimertinib, have all shown to be effective in this setting. Osimertinib, a third-generation EGFR TKI, is a favorable option, but almost all patients develop resistance at some time point. There are no effective treatment options for patients who progress on osimertinib, but ongoing trials will hopefully address this unmet need. The aim of this review is to provide a comprehensive review of the data with EGFR TKIs, management of the toxicities and the ongoing trials with this class of agents.Keywords: non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitor
format	article
author	Lee CS Sharma S Miao E Mensah C Sullivan K Seetharamu N
author_facet	Lee CS Sharma S Miao E Mensah C Sullivan K Seetharamu N
author_sort	Lee CS
title	A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
title_short	A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
title_full	A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
title_fullStr	A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
title_full_unstemmed	A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
title_sort	comprehensive review of contemporary literature for epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer and their toxicity
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/8b542e20ae0a4c32b9f76e780154d06b
work_keys_str_mv	AT leecs acomprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT sharmas acomprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT miaoe acomprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT mensahc acomprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT sullivank acomprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT seetharamun acomprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT leecs comprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT sharmas comprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT miaoe comprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT mensahc comprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT sullivank comprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity AT seetharamun comprehensivereviewofcontemporaryliteratureforepidermalgrowthfactorreceptortyrosinekinaseinhibitorsinnonsmallcelllungcancerandtheirtoxicity
_version_	1718393636351115264

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity

Ejemplares similares